Getting To Implementation: Improving Cancer Screening for Veterans
Launched by UNIVERSITY OF PITTSBURGH · Jun 12, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Researchers will conduct two hybrid type 3, cluster-randomized trials to compare the effectiveness of Patient Navigation (PN) and Implementation Facilitation (IF) on hepatocellular cancer (HCC) and colorectal cancer (CRC) screening completion. Trials will enroll 24 sites for the HCC arm and 32 sites for the CRC arm, passively enrolling and cluster-randomizing Veterans by their site of primary care. Multi-level implementation determinants (i.e., barriers and facilitators), preconditions, and moderators will also be evaluated pre- and post-intervention, using Consolidated Framework for Implem...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Veterans:
- • ≥18 years of age
- • Enrolled in Veterans Health Administration (VA)
- • Have ≥1 VA encounter in the prior 18 months
- • Hepatocellular cancer (HCC) screening subgroup: Diagnosis of cirrhosis in electronic medical record
- • Colorectal cancer (CRC) screening subgroup: ≥45 years of age, positive fecal immunochemical test (FIT) (or other screening stool test) in the last 18 months
- 2. Providers:
- • Healthcare provider or related staff at participating VA site or engaged in CRC or HCC screening pathways in an included VA site (e.g., scheduling)
- • ≥18 years of age
- Exclusion Criteria:
- 1. Veterans:
- • \<18 years of age
- • Not enrolled in VA
- • No VA encounters in the prior 18 months
- • Limited life expectancy (\< 6 months), defined as having a code for hospice
- 2. Providers:
- • Members of the study team will not participate, even if their sites are recruited
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Shari S Rogal, MD, MPH
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported